update, page-136

Hi 1S1,

I certainly understand your concerns about capital availability with these biospecs. They seem to chew up the dollars on some vague hope that one day they will make a killing. This is certainly the case for a couple of other biospecs that I own.

One is trying to complete PhIII trials in Africa (which is problematic enough) and has an convertible note redemption at the end of next month which may leave with capital for only another couple of quarters.

The other has a product in the market, which according to anectotal evidence seems to work really well, but staff costs are very high and unless sales this quarter blow the lights out are going to have to tap the market again this year.

But by my read OBJ is different. Here's a graph of costs and cash available. I reckon at the current cash burn rate of (conservatively) 370K/quarter and 3.7 million in the bank these guys have got 10 quarters of cash available. I wish my other speccies had the same.

Anyway if you get back in to OBJ I might see ya at the AGM

cheers

bluebush